Provided by Tiger Trade Technology Pte. Ltd.

Eloxx Pharmaceuticals (Uplisting)

20.98
+2.9416.27%
Post-market: 20.980.00000.00%19:37 EDT
Volume:93.39K
Turnover:2.00M
Market Cap:84.66M
PE:-7.36
High:23.40
Open:19.00
Low:18.04
Close:18.04
52wk High:23.40
52wk Low:0.0000
Shares:4.04M
Float Shares:2.39M
Volume Ratio:2.35
T/O Rate:3.91%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-2.8493
EPS(LYR):-183.1293
ROE:-615.23%
ROA:-97.59%
PB:1.82
PE(LYR):-0.11

Loading ...

Company Profile

Company Name:
Eloxx Pharmaceuticals (Uplisting)
Exchange:
NASDAQ
Establishment Date:
1999
Employees:
10
Office Location:
P.O. Box 274,Arlington,Massachusetts,United States
Zip Code:
02476
Fax:
- -
Introduction:
Eloxx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing ribosome modulation for the treatment of rare and ultra-rare premature stop codon diseases. Its lead investigational drug product candidate is ELX-02, which is in Phase 2 clinical trial for the treatment of cystic fibrosis and nephropathic cystinosis patients with diagnosed nonsense mutations. The company also develops various preclinical programs for the treatment of alport syndrome, recessive dystrophic epidermolysis bullosa, junctional epidermolysis bullosa, and familial adenomatous polyposis, as well as various earlier discovery stage programs in oncology. Eloxx Pharmaceuticals, Inc. was founded in 2013 and is headquartered in Watertown, Massachusetts.

Directors

Name
Position
Alan Walts
Chairman and Director
Sumit Aggarwal
Chief Executive Officer and Director
Nina Kjellson
Director
Stephen W. Webster
Director
Steven D. Rubin
Director

Shareholders

Name
Position
Sumit Aggarwal
Chief Executive Officer and Director
Daniel E. Geffken
Interim Chief Financial Officer